Safe Supply Streaming Endorses B.C. Government’s Expansion of Safer-Supply Program amid Drug Crisis

Vancouver, British Columbia–(Newsfile Corp. – February 5, 2024) – Safe Supply Streaming Co. Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) (“Safe Supply” or “the Company”), a pioneering company dedicated to fostering safer and healthier communities through investing, partnering, incubating and accelerating companies operating across the scheduled narcotics ecosystem, applauds the recent call by Dr. Bonnie Henry for the expansion of the safer-supply program in British Columbia.

The safer-supply program, a first of its kind in B.C., enables medical professionals to prescribe regulated opioids to substance users, aiming to mitigate the dangers associated with illicit drug use. Dr. Henry’s report highlights the urgent need for a broader spectrum of prescription drugs to combat the province’s drug crisis, despite potential risks of diversion.

Recognizing the societal risks, Dr. Henry has recommended the formation of a scientific and clinical committee to monitor and address any arising issues, a move that Safe Supply Streaming fully supports. Henry’s report says that currently, based on evidence that is available, “a safer supply policy can be ethically defended and prioritized”. She says while they can’t yet say prescribed safer supply is evidence-based, because there simply isn’t enough evidence out there, what is available is promising. “Evidence alone never tells you what to do. It has to be put in the context and understanding of what’s happening in the community and in the areas around the evidence.”

Major media outlets like CBC and Global News have picked up on this.

Safe Supply Streaming as an organization is determined to work alongside the government and Health Canada officials to tackle the fentanyl crisis that plagues communities across the nation.

“Safe Supply Streaming stands at the forefront of this public health challenge, contributing to a framework that supports the well-being of individuals and the safety of our communities,” said Bill Panagiotakopoulos, CEO of Safe Supply. “Our investment and partnership strategies are geared towards companies that not only share our vision for a harm-reduced future but also demonstrate potential for sustainable and impactful solutions.”

The Company also supports the establishment of ethics committees and the utilization of data to inform and guide policies and practices. This data-driven approach is crucial for understanding the complexities of the drug crisis and for developing strategies that prioritize human dignity and public health. This endorsement reflects Safe Supply’s ethos of embracing responsible and ethical practices while seeking new opportunities for investors.

The Company’s focus on contributing to a robust healthcare infrastructure positions it as a leader in the movement to alleviate the consequences of the opioid epidemic. As a part of its commitment to creating a safer ecosystem in healthcare, Safe Supply is actively incubating, accelerating, and investing in companies poised to offer innovative solutions ranging from harm reduction and testing to addiction treatment facilities.

About Safe Supply

Safe Supply Streaming Co. Ltd. is a public company committed to reducing the harm caused by the opioid crisis. Through strategic investments in healthcare, legal, and regulatory sectors, the company supports and partners with businesses that develop innovative and ethical solutions for addiction treatment and drug testing.

SafeSupply Streaming is dedicated to fostering a safer and healthier future for all. Learn more at www.safesupply.com and follow Safe Supply on LinkedIn, Twitter, and Instagram.

For Further Information:

Bill Panagiotakopoulos
Chief Executive Officer and Director
Safe Supply Streaming Co. Ltd.
www.safesupply.com
safesupply@grovecorp.ca

Media contacts:
McKenna Miller
KCSA Strategic Communications
safesupply@kcsa.com

Forward-Looking Information and Statements

Certain statements in this news release related to Safe Supply and Origin are forward-looking statements and are prospective in nature, including but not limited to the express or implied statements and assumptions regarding the intention of Origin and Safe Supply to complete the Transaction. Forward-Looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These forward-looking statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “will” or “continue”, or the negative thereof or similar variations. There are numerous risks and uncertainties that could cause actual results and Origin’s and Safe Supply’s plans and objectives to differ materially from those expressed in the forward-looking information, including but not limited to adverse market conditions and risks inherent in Origin’s and Safe Supply’s respective businesses. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this press release. Except as required by applicable law, Origin and Safe Supply do not intend to update these forward-looking statements. Without limiting the generality of the foregoing, there can be no assurance that the Transaction will be completed as proposed, or at all. Investors are cautioned that, except as disclosed in the management information circular and/or listing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Origin should be considered highly speculative.

The CSE has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/196821